Johnny Mahlangu to Hemostatics
This is a "connection" page, showing publications Johnny Mahlangu has written about Hemostatics.
Connection Strength
1,522
-
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. Haemophilia. 2017 Jan; 23(1):67-76.
Score: 0,531
-
FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic. J Thromb Haemost. 2024 Apr; 22(4):990-1000.
Score: 0,222
-
Unexplained hemorrhagic syndrome? Consider acquired hemophilia A or B. Blood Rev. 2022 05; 53:100907.
Score: 0,191
-
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia. 2021 Nov; 27(6):911-920.
Score: 0,190
-
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8.
Score: 0,129
-
Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76.
Score: 0,129
-
Guidelines for the management of hemophilia. Haemophilia. 2013 Jan; 19(1):e1-47.
Score: 0,100
-
Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey. Haemophilia. 2015 Sep; 21(5):589-97.
Score: 0,030